Inhibikase Therapeutics (IKT) vs Lexeo Therapeutics (LXEO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Inhibikase Therapeutics (IKT) has outperformed Lexeo Therapeutics (LXEO) over the past year, gaining 15.1% versus a loss of 60.0%. Inhibikase Therapeutics is the larger company by market cap ($267.9 million vs $262.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IKT | LXEO |
|---|---|---|
| Share price | $1.92 | $3.20 |
| Market cap | $267.91M | $262.68M |
| 1-day change | +0.52% | -0.31% |
| YTD return | -6.83% | -67.67% |
| 1-year return | +15.06% | -60.02% |
| 5-year return | -83.51% | — |
| EPS (TTM) | $-0.43 | $-1.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.61 | $10.99 |
| 52-week low | $1.33 | $2.98 |
| Distance from 52-week high | -26.44% | -70.88% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +212.50% | +534.38% |
| Average volume | 652.84K | 1.20M |
| Shares outstanding | 139.54M | 82.09M |
| Employees | 35 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IKT has outperformed LXEO by 75.1 percentage points over the past year.
About Inhibikase Therapeutics
IKT stock →Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
About Lexeo Therapeutics
LXEO stock →Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 63 employees
IKT vs LXEO FAQ
Which is bigger, Inhibikase Therapeutics or Lexeo Therapeutics?
Inhibikase Therapeutics (IKT) is larger, with a market capitalization of $267.91M compared with $262.68M for Lexeo Therapeutics (LXEO).
Which stock has performed better over the past year, IKT or LXEO?
IKT returned +15.06% over the past 12 months, compared with -60.02% for LXEO (price return, excluding dividends). Past performance does not predict future results.
Are Inhibikase Therapeutics and Lexeo Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.